Outcomes of Patients with Squamous Cell Carcinoma of Esophagus who did not receive Surgical Resection after Neoadjuvant Radiochemotherapy

Author:

Fakhrian Khashayar12,Ordu Arif Deniz2,Nieder Carsten3,Lordick Florian45,Kup Philipp Günther1,Theisen Jörg6,Combs Stephanie E.2,Geinitz Hans27

Affiliation:

1. Department of Radiation Oncology, Marien Hospital Herne, Ruhr-University Bochum, Herne - Germany

2. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München, Munich - Germany

3. Department of Oncology and Palliative Medicine, Nordland Hospital Trust, Bodø, and Institute of Clinical Medicine, Faculty of Health Sciences, University of Tromsø, Bodø - Norway

4. University Cancer Center Leipzig (UCCL), University Clinic Leipzig, Leipzig - Germany

5. Department of Internal Medicine III (Hematology/Oncology), Klinikum rechts der Isar, Technische Universität München, Munich - Germany

6. Department of Surgery, Klinikum rechts der Isar, Technische Universität München, Munich - Germany

7. Department of Radiation Oncology, Krankenhaus der Barmherzigen Schwestern Linz, Linz - Austria

Abstract

Aims and Background The primary objective was to assess the different reasons for refusal of surgical resection (SR) in patients with esophageal squamous cell cancer (ESCC), who were initially planned for neoadjuvant radiochemotherapy (N-RCT) + SR, but SR was not performed after N-RCT. Methods and Study Design From 1988 to 2011, 311 patients with ESCC were treated with N-RCT in a tertiary referral center for esophageal diseases. Fifty-three patients were analyzed who received RCT with 40–45 Gy and concomitant chemotherapy in neoadjuvant intention, but in whom the treatment was stopped or switched to definitive RCT due to progression, patient decision, or new findings. Results The reasons for refusal of SR for these 53 patients were as follows: ( 1 ) patients' or physicians' preference for the planned treatment was changed during the N-RCT, such that RCT was continued to a curative dose without a break (group 1, n = 23, 44%); ( 2 ) patients were restaged after 4 weeks, and the tumor board decided to continue RCT because RO resection was unlikely and/or patients were medically unfit (group 2, n = 15, 28%); ( 3 ) patients refused continuation of any treatment (group 3, n = 15, 28%). Refusal of SR was significantly more likely in patients with longitudinal tumor dimension >8 cm and those with an Eastern Cooperative Oncology Group performance status score of 2. Median follow-up time from the start of N-RCT was 57 months (range 1–137 months). The survival rates at 2 and 5 years were 36 ± 7% and 27 ± 7%, respectively. Group 1 had significantly longer survival. Conclusions The planned N-RCT+SR could not be completed in a considerable number of patients in a tertiary referral center. More strict selection criteria for multimodality treatment including SR could spare some of these patients an incomplete treatment and probably lead to increased utilization of definitive RCT.

Publisher

SAGE Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3